Lonigutamab

DB18940InvestigationalProtein Based Therapies

Lonigutamab is under investigation in clinical trial NCT05683496 (Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)).

Mechanism
Curator reviewed
Also known as
Immunoglobulin g1 (de-c-terminal-lysine), anti-(human insulin-like growth factor i receptor) (human-mus musculus monoclonal hz208f2-4 .gamma.1-chain), disulfide with human-mus musculus monoclonal hz208f2-4 .kappa.-chain, dimer · Immunoglobulin g1-kappa, anti-(homo sapiens igf1r (insulin like growth factor 1 receptor, igf1-r, igf-1r, cd221)), humanized monoclonal antibody
Code names
VB-421

Resolves to

Compound
UNII56GN9PT35DCAS2362015-67-4
Targets
P08069IGF1R

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lonigutamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In